Market Research Reports Global Viral Vector Manufacturing Market 2019 | Page 2

genetic disorders & infectious diseases. However, the market growth is restricted by the high risk of
undesirable outcomes. The significant developments in Gene therapy to cure rare diseases such as
cancer, chronic diseases and also some genetic disorders, are leading the increasing number of
clinical trials.
The high number of active clinical trials to get to the security of the viral vector vaccine in the North
America area has likewise given a noteworthy driving force to the Viral Vector Manufacturing
Market. For example, as of 2016, a clinical study named Dose-Ranging trial of safety &
immunogenicity of an oral adenoviral-vector based RSV vaccine is going-on in Optimal Research
Melbourne, Florida (United States), in order to detect respiratory syncytial virus (RSV). On March
2017, as per the official website of the company named American Gene Technologies International
Inc (United States), has collaborated with Geo Vax Labs Inc to conduct a Phase 1 clinical trial
investing AGT’s viral vector vaccines to cure HIV infection. Viral vector-based vaccines are considered
one of the most promising candidates for vaccine development; hence growing R&D expenditure for
the development of new medicines in North America presents a huge opportunity for the growth of
Viral Vector Manufacturing Market.
The Global Viral Vector Manufacturing Market is segmented on the basis of Type, Disease,
Application, Industry and Region. By Type of disease, the Global Viral Vector Manufacturing Market
is segmented into Genetic disorders, infectious disease, cancers and others. Currently the market is
dominated by Cancer disease with 46.75% revenue share in 2017. Based on the Type, the Global
Viral Vector Manufacturing Market is sub-segmented into Adenoviral, Retroviral, Adeno-associated
viral and others. Among these retroviral holds the largest revenue share of 32.37% in 2017. Viral
vectors are promising tools for gene therapy and vaccines. The viral vector vaccine segment was
anticipated to dominate the revenue share in 2015 with 53.43% revenue share in 2015. However,
gene therapy segment is anticipated to surpass the global revenue share in 2018.
Current Industry News:
Lonza (May 16, 2019) – Lonza Launches Capsugel Zephyr - New Dry-Powder Inhalation Capsule
Portfolio – Today Lonza announced the launch of Capsugel Zephyr, its new dry-powder inhalation
(DPI) capsule portfolio, the most complete portfolio of DPI capsules to meet the growing need for
customized solutions for optimal pulmonary drug delivery.
Respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are on the rise
globally and are among the most life-threatening. Lonza’s Capsule Delivery Solutions team
developed Capsugel Zephyr capsules as a portfolio of high-quality, highly customizable DPI capsules
of different polymers and compositions, and product customization services to help address the
specific needs of inhalation drug products manufacturers.
Top Leading Key Manufacturers are: Wuxi Apptec, CGT Catapult, Lonza, UniQure, Merck, Cobra
Biologics, Oxford BioMedica, Fujifilm Diosynth Biotechnologics and others. New product launches
and continuous technological innovations are the key strategies adopted by the major players.
Purchase this report online with 200 Pages, List of Tables & Figures and in-depth Table of Contents
on “Global Viral Vector Manufacturing Market Report 2019” @
https://www.businessindustryreports.com/buy-now/157804/single .